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ABSTRACT
Introduction: To assess the correlation among 18F-FDG uptake, Glut1, pStat1 
and pStat3, and to investigate the relationship between the prognosis and 18F-FDG 
uptake and these molecular markers in surgically resected non-small cell lung cancer 
(NSCLC) patients.
Results: Knockdown of Glut1 led to a significant increase in pStat1 expression. 
Glut1 expression positively correlated with the SUVmax, SUVmean, and TLG 
significantly (P<0.001). pStat3 expression negatively correlated with all PET 
parameters significantly (P<0.001). pStat1 had positive weak correlations with the 
SUVmax and SUVmean. All PET parameters and Glut1 were significantly associated 
with DFS (P<0.05). TLG, MTV, Glut1 and pStat1 were significantly associated with 
OS (P<0.05).
Conclusion: pStat3 and Glut1 may be associated with 18F-FDG uptake mechanism. 
TLG, MTV, and Glut1 may be independent prognostic factors.
Methods: The SUVmax, SUVmean, MTV and TLG of primary lesions were 
calculated in 140 patients. The expressions of Glut1 and Stat pathway proteins in 
NSCLC cell lines were examined by immune blots. Excised tumor tissue was analyzed 
by immunohistochemistry. OS and DFS were evaluated by the Kaplan-Meier method. 
The difference in survival between subgroups was analyzed by log-rank test. The 
prognostic significance of clinicopathological, molecular and PET parameters was 
assessed by Cox proportional hazard regression analysis.
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INTRODUCTION
Lung cancer is the leading cause of cancer death 
among men and women worldwide; an estimated 
1.8 million new lung cancer cases occurred in 2012, 
accounting for approximately 13% of total cancer 
diagnoses [1]. The TNM staging system has been used as 
the most important prognostic factor for many types of 
cancer, but this staging system is considered not to predict 
the prognosis of non-small cell lung cancer (NSCLC) 
accurately, because it does not include molecular 
biological information.
The SUVmax has been reported to be an 
independent prognostic factor in NSCLC patients [2]. 
However, SUVmax reflects only the maximum glucose 
metabolism as measured in the highest pixels within a 
designated region of interest, which does not always 
reveal the glucose metabolism within the whole tumor. 
The TLG and the MTV are also taken into consideration 
as representative volumetric parameters to estimate the 
total radioactivity throughout a tumor above a minimum 
threshold, and these two parameters have been useful in 
predicting the prognosis and tumor response for malignant 
tumors [3, 4].
Glut1 expression contributes to the 18F-FDG uptake 
mechanism of malignant tumors because high glycolysis 
rate is observed in cancer cells. Stat1 is transferred to 
pStat1 by JAK phosphorylation, and the overexpression 
of the Stat1/INF pathway has been recently reported 
to be related with the resistance of chemotherapy and 
radiotherapy, metastasis, and poor prognosis in malignant 
tumors [5, 6].
Stat3 is activated by mutant EGFR and JAK, and 
notably, pStat3 is associated with tumor cell proliferation 
and angiogenesis [7]. To our knowledge, there are no 
reports regarding the correlation between 18F-FDG uptake 
and the Stat pathway, or investigations of the prognosis 
of NSCLC patients using volumetric parameters, Glut1, 
pStat1 and pStat3. We conducted the present study 
to assess the correlations between 18F-FDG uptake 
and Glut1, pStat1 and pStat3 and to investigate the 
relationship among the prognosis, volumetric parameters 
and molecular markers in completely resected NSCLC 
patients.
RESULTS
The correlation between PET parameters and 
clinicopathological variables
Our analyses revealed that TLG had significant 
positive correlations with the SUVmax (R = 0.723, P < 
0.001), SUVmean (R = 0.697, P < 0.001) and MTV (R 
= 0.881, P < 0.001). The MTV also showed significant 
positive correlations with the SUVmax (R = 0.349, 
P < 0.001) and SUVmean (R = 0.306, P = 0.002). The 
details of the relationships between PET parameters 
and clinicopathological variables are summarized in 
Table 1. Patient age, gender, and pStage were each 
significantly associated with all PET parameters. Adjuvant 
chemotherapy was not associated with the SUVmean or 
SUVmax, but it was significantly associated with MTV 
(P = 0.011) and TLG (P = 0.008). Histology and smoking 
status were significantly associated with the SUVmax, 
SUVmean and TLG, but not with MTV. Only TLG showed 
significant associations with all of the clinicopathological 
variables.
Effects of Glut1 knockdown on the expression of 
Stat pathway proteins in human NSCLC Cells
Given the significant correlations between 18F-FDG 
uptake and Glut1 expression in this analysis and a previous 
study [8], we examined the expression of Glut1 in lung 
cell lines. A high expression of Glut1 was observed in the 
HCC827, EBC1, NCI-H1993, and Calu1cell lines, but not 
in the other cell lines.
We then examined the effect of Glut1 knockdown 
using cognate siRNA on the expressions of pStat1 and 
pStat3 proteins (Figure 1A). Transient knockdown by the 
transfection of HCC827, EBC1, and NCI-H1993 cells 
with Glut1 siRNA increased the expressions of pStat1, but 
did not change the expression of pStat3 (Figure 1B). These 
results indicate that Glut1 is associated with the Stat signal 
pathway in human lung cancer cells.
The correlations between PET parameters and 
molecular markers
The relationships between 18F-FDG parameters and 
Glut1, pStat1, and pStat3 are summarized in Table 2. The 
Glut1 expression had significant positive correlations 
with the SUVmax (R = 0.62, P < 0.001), SUVmean (R 
= 0.611, P < 0.001), and TLG (R = 0.359, P < 0.001), 
but not with MTV. The pStat3 expression had significant 
negative correlations with the SUVmax (R = -0.577, P 
< 0.001), SUVmean (R= -0.586, P < 0.001), MTV (R= 
-0.215, P < 0.001), and TLG (R= -0.435 P < 0.001). The 
pStat1 expression showed significant positive correlations 
with the SUVmax and SUVmean, but not with MTV and 
TLG. A representative patient's case is shown in Figure 2.
Associations among PET parameters, molecular 
markers, and survival
The median follow-up period was 1,198 days (range 
192–2,834 days). Sixty-five of the 140 patients (46.1%) 
developed local recurrence or distant metastases, and 37 
(26.2%) of the 140 patients died during the study period. 
The Kaplan-Meier survival curves for DFS and OS are 
shown (Figures 3 and 4). The optimal cut-off values for 
what were as follows: SUVmax, 3.0; SUVmean, 1.5; 
Oncotarget31973www.oncotarget.com
MTV, 10.0; TLG, 6.0; Glut1 score, 110; pStat1 score, 3.0; 
and pStat3 score, 85. On both the DFS and OS for Kaplan-
Meier survival curves, the survival curves of the groups of 
patients with low SUVmean, low SUVmax, low MTV, and 
low TLG are significantly longer than those of the high 
groups, as follows. SUVmean: DFS, P = 0.004, OS, P = 
0.005; SUVmax: DFS, P = 0.002, OS, P = 0.007; MTV: 
DFS, P = 0.024, OS, P = 0.023; TLG: DFS, P < 0.001, OS, 
P = 0.001. The survival curves of the patients with high 
Glut1 or low pStat3 expression were significantly shorter 
than those of the patients with low Glut1 or high pStat3, 
with the following values. Glut1: DFS, P = 0.005, OS, P < 
0.001; pStat3: DFS, P = 0.019, OS, P = 0.024. There was 
no significant difference in DFS or OS between the low-
pStat1 expression group and the high-pStat1 expression 
group.
The details of the results of the Cox proportional 
hazard model for OS and DFS are provided (Tables 3 
and 4). After adjusting for potential confounding factors, 
all PET parameters and Glut1 remained significantly 
correlated with DFS (SUVmax: HR = 1.443: 95% CI 
1.023–2.034, P = 0.037; SUVmean: HR = 1.404, 95%CI 
1.013–1.946, P = 0.042; MTV: HR = 1.199, 95%CI 1.085–
1.324, P < 0.001; TLG: HR = 1.134, 95%CI 1.064–1.208, 
P < 0.001; Glut1: HR = 3.636, 95%CI 1.981–6.673, P < 
0.001). Regarding OS, our analyses revealed that TLG, 
MTV, Glut1 and pStat1 remained significantly correlated 
with the OS (MTV: HR = 1.244, 95%CI 1.111–1.393, 
P < 0.001; TLG: HR = 1.172, 95%CI 1.083–1.268, P < 
0.001; Glut1: HR = 3.569, 95%CI 1.534–8.304, P = 0.003; 
pStat1: HR = 1.260, 95%CI, 1.022–1.553; P = 0.031). 
pStat1 and pStat3 were not significantly related to the 
DFS (pStat1: HR = 1.099, 95%CI, 0.957–1.262; P = 0.18, 
pStat3: HR = 0.779, 95%CI, 0.511–1.188; P = 0.246), and 
the SUVmax, SUVmean, and pStat3 were not significantly 
associated with the OS (SUVmax: HR = 1.227, 95%CI, 
0.738–2.039; P = 0.431, SUVmean: HR = 1.232, 95%CI, 
0.753–2.016; P = 0.405, pStat3: HR = 0.815, 95%CI, 
0.421–1.578; P = 0.544).
DISCUSSION
The amount of 18F-FDG accumulation has been 
reported to be associated with molecules relevant to 
glucose metabolism, hypoxia (HIF-1α), angiogenesis 
(CD43, VEGF) and mTOR signaling pathway, and PTEN 
in NSCLC patients [8]. The correlation between 18F-FDG 
uptake in primary tumor and these molecular markers 
has been examined in head neck cancer, pancreas cancer 
and uterine cervical cancer patients [9–11]. Mano et al. 
Table 1: The relationship between 18F-FDG uptake and clinicopathological variables
Clinicopathological 
variables SUVmax P SUVmean P MTV P TLG P
Histology         
 Adeno (n=114) 3.29(1.83,5.07) <0.001 2.02(1.21,3.48) <0.001 3.90(2.11,9.00) <0.001 8.17(3.40,21.28) 0.002
 Sq (n=26) 6.30(4.99,9.01)  3.94(3.02,5.54)  5.71(3.27,16.54)  27.57(8.12,77.94)  
Smoking status         
 None (n=63) 2.67(1.68,4.89) 0.002 1.56(1.19,3.12) 0.002 3.42(2.08,8.35) 0.064 6.13(3.20,14.83) 0.004
 Smoker (n=77) 4.76(2.53,6.62)  2.89(1.57,4.23)  4.75(2.62,14.12)  12.75(4.62,37.36)  
pStage         
 Stage I (n=91) 2.68(1.81,5.67) 0.003 1.66(1.19,3.61) 0.003 3.39(2.08,7.73) 0.003 6.13(3.45,17.41) <0.001
 Stage II,III (n=49) 4.88(3.40,6.47)  3.02(2.07,4.22)  6.75(3.20,15.96)  20.38(8.12,51.51)  
Adjuvant therapy         
 Absent (n=88) 3.11(1.85,5.97) 0.157 1.91(1.19,3.80) 0.219 3.37(2.21,6.98) 0.011 6.36(3.94,20.38) 0.008
 Present(n=52) 4.41(2.67,6.18)  2.81(1.54,3.98)  8.29(2.69,14.12)  19.31(5.24,37.36)  
Gender         
 Men (n=85) 4.76(2.32,6.62) 0.001 2.89(1.52,4.23) 0.002 4.93(2.59,15.26) 0.03 12.75(4.20,50.55) 0.003
 Women (n=55) 2.67(1.68,4.82)  1.59(1.19,3.03)  3.32(2.08,8.35)  5.86(3.49,14.14)  
Age         
 <73 (n=66) 3.07(1.83,4.99) 0.002 1.90(1.20,3.21) 0.005 3.28(2.10,7.43) 0.011 5.72(3.10,16.94) <0.001
 73≥– (n=74) 4.82(2.21,7.34)  2.96(1.40,4.38)  4.83(2.98,14.69)  14.14(5.10,34.24)  
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demonstrated that 18F-FDG uptake is associated with the 
expressions of pStat3, HIF-1α and Glut1 in hepatocellular 
carcinoma, and that pStat3 had a significant positive 
correlation with 18F-FDG accumulation [12]. However, 
to our knowledge, the relationship between 18F-FDG 
uptake mechanism and pStat pathway and the correlation 
between Glut1 and pStat pathway have not been clarified 
in NSCLC patients. We examined the effect of Glut1 
knockdown using cognate siRNA on the expression 
of pStat proteins. The transient knockdown by the 
transfection of NSCLC cells with Glut1 siRNA increased 
the expression of pStat1. Based on those results, we 
conducted an immunohistochemical staining examination 
of Glut1, pStat1 and pStat3 in the 140 NSCLC patients.
The SUVmax, SUVmean and TLG each had a 
significant positive correlation with Glut1. All PET 
parameters had a significant inverse correlation with 
pStat3 expression. Koh et al. reported that high values of 
volumetric parameters were significantly higher in Glut1-
positive compared to Glut1-negative adenocarcinoma 
[13]. Harura et al. suggested that high pStat3 expression 
was related to smaller tumor size, limited smoking, and 
an anti-apoptosis effect on early NSCLC, and that agents 
targeting the EGFR-Stat3 pathway may have better 
efficiency in early-stage NSCLC patients compared to 
advanced-stage patients [14]. The inverse correlation 
between 18F-FDG uptake and pStat3 expression may be 
due to the EGFR-Stat3 pathway. Unfortunately, these 
Figure 1: Effects of Glut1 knockdown on the expression of Stat signal pathway proteins in human lung cell lines. 
(A) A high expression of Glut1 was observed in the HCC827, EBC1, NCI-H1993, and Calu1cell lines. (B) Transient knockdown by the 
transfection of HCC827, EBC1, and NCI-H1993 cells with Glut1 siRNA increased the expressions of pStat1, but did not change the 
expression of pStat3.
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correlations between pStat1 and SUVmax and SUVmean 
are weak, and volumetric parameters did not correlate with 
pStat1. pStat3 and Glut1 expression rather than pStat1 
expression may modulate the 18F-FDG uptake in NSCLC.
Research regarding a pStat3 inhibitor, OPB-51602, 
has been progressing [15]. 18F-FDG uptake may be a 
promising biomarker for predicting pStat3 expression 
in response to molecular target therapy. However, our 
data about correlation between18F-FDG accumulation 
and pStat3 expression was not agreement with Mano et 
al. [12]. The correlation between pStat3 expression and 
18F-FDG uptake may differ by the type of cancer. This 
correlation should be investigated in other malignant 
tumors.
Volumetric parameters have been reported to be 
useful to predict the tumor response and the prognosis 
after chemotherapy in advanced NSCLC [16]. Regarding 
preoperative NSCLC patients, Kim et al. reported that 
the MTV was the only significant prognostic factor for 
OS in their multivariate analysis of stage I–IIIA patients 
[17]. Hyum et al. found that in addition to pathological 
TNM stage, volumetric parameters were independent 
prognostic factors for both OS and DFS in stage I–II 
patients [18]. TLG was a significant prognostic factor for 
OS in stage I patients, as described by Park et al. [19]. Our 
present findings are in agreement with Hyum et al. [18]. 
However, Domachevsky et al. reported that the SUVmax 
was a more useful independent prognostic marker than 
volumetric parameters in patients with stage I–II NSCLC, 
and Lin et al. suggested that the SUVmax was the only 
parameter for the DFS of patients with stage I NSCLC 
[20, 21]. The usefulness of volumetric parameters for 
Figure 2: Example of NSCLC (adenocarcinoma; pT2N0M0 stage IIA) in an 81-yr-old man. High 18F-FDG uptake is 
observed in the right upper lung field. (A) MIP image. (B) Axial PET image. SUVmean: 5.39, SUVmax: 8.30, MTV: 110.3, and TLG: 
595.31. (C) The Glut1 score was 210. (D) The pStat1 expression score was 1. (E) The pStat3 expression score was 30.
Table 2: The relationship between 18F-FDG uptake and molecular markers
Molecular biological 
markers Glut1 P pStat1 P pStat3 P
SUVmax R=0.62 <0.001 R=0.171 0.043 R=-0.577 <0.001
SUVmean R=0.611 <0.001 R=0.168 0.046 R=-0.568 <0.001
MTV R=0.103 0.224 R=0.051 0.546 R=-0.215 0.017
TLG R=0.359 <0.001 R=0.116 0.171 R=-0.435 <0.001
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predicting the prognosis of patients with resected NSCLC 
thus remains controversial and should be investigated in 
greater numbers of patients.
The advantage of this study compared to prior 
investigations is that we examined the prognosis of 
NSCLC using four PET parameters and molecular 
markers, and we revealed the correlations between 
18F-FDG uptake and molecular markers using 
immunohistochemical staining examination and immune 
blots. Our present study demonstrated that Glut1 is a 
prognostic factor for NSCLC patients. Nguyen et al. 
reported that the 18F-FDG uptake is more valuable than 
Figure 3: Kaplan-Meier estimates of survival functions for DFS in the low and high groups for the SUVmean, SUVmax, 
MTV, TLG, Glut1, pStat1, and pStat3 in the 140 NSCLC patients. P-values were determined by the log-rank test.
Figure 4: Kaplan-Meier estimates of survival functions for OS in the low and high groups for the SUV mean, SUVmax, 
MTV, TLG, Glut1, pStat1, and pStat3 in 140 NSCLC patients. P-values were determined by the log-rank test.
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Table 3: Results of Cox regression analysis for DFS
 
 
DFS (Full model) DFS (Reduced model) 
HR(95%CI) P HR(95%CI) P
SUVmax(Unit=q3-q1) 1.377( 0.962, 1.970) 0.08 1.443( 1.023, 2.034) 0.037
pStage (II,III/I) 2.068( 1.213, 3.524) 0.008 2.170( 1.311, 3.590) 0.003
Adjuvant (Present/Absent) 1.411( 0.812, 2.455) 0.222   
Age (Unit=10) 1.307( 0.985, 1.736) 0.064 1.229( 0.940, 1.607) 0.131
Gender (Women/Men) 0.760( 0.386, 1.493) 0.425   
Smoking (Smoker/Never) 1.607( 0.864, 2.990) 0.134   
Histology (Adeno/Sq) 1.821( 0.864, 3.836) 0.115 1.558( 0.728, 3.336) 0.253
     
SUVmean(Unit=q3-q1) 1.331( 0.953, 1.861) 0.094 1.404( 1.013, 1.946) 0.042
pStage (II,III/I) 2.109( 1.241, 3.585) 0.006 2.222( 1.348, 3.662) 0.002
Adjuvant (Present/Absent) 1.409( 0.810, 2.450) 0.225   
Age (Unit=10) 1.311( 0.988, 1.740) 0.06 1.232( 0.943, 1.610) 0.126
Gender (Women/Men) 0.743( 0.379, 1.455) 0.386   
Smoking (Smoker/Never) 1.581( 0.848, 2.946) 0.149   
Histology (Adeno/Sq) 1.800( 0.855, 3.790) 0.122 1.537( 0.720, 3.279) 0.267
     
MTV(Unit=q3-q1) 1.156( 1.038, 1.287) 0.008 1.199( 1.085, 1.324) <0.001
pStage (II,III/I) 1.990( 1.155, 3.430) 0.013 2.042( 1.221, 3.413) 0.006
Adjuvant (Present/Absent) 1.275( 0.726, 2.238) 0.398   
Age (Unit=10) 1.280( 0.963, 1.700) 0.089 1.228( 0.940, 1.604) 0.133
Gender (Women/Men) 0.747( 0.381, 1.467) 0.397   
Smoking (Smoker/Never) 1.460( 0.776, 2.745) 0.241   
Histology (Adeno/Sq) 1.370( 0.686, 2.735) 0.372 1.101( 0.567, 2.134) 0.777
     
TLG(Unit=q3-q1) 1.108( 1.036, 1.185) 0.003 1.134( 1.064, 1.208) <0.001
pStage (II,III/I) 2.036( 1.182, 3.507) 0.01 2.088( 1.254, 3.475) 0.005
Adjuvant (Present/Absent) 1.273( 0.726, 2.234) 0.4   
Age (Unit=10) 1.276( 0.962, 1.693) 0.09 1.226( 0.938, 1.602) 0.135
Gender (Women/Men) 0.757( 0.386, 1.484) 0.418   
Smoking (Smoker/Never) 1.480( 0.788, 2.779) 0.223   
Histology (Adeno/Sq) 1.425( 0.714, 2.841) 0.315 1.156( 0.597, 2.238) 0.667
     
Glut1score(High/Low) 3.098( 1.622, 5.917) 0.001 3.636( 1.981, 6.673) <0.001
pStage (II,III/I) 2.235( 1.295, 3.856) 0.004 2.484( 1.510, 4.088) <0.001
Adjuvant (Present/Absent) 1.366( 0.777, 2.403) 0.279   
Age (Unit=10) 1.382( 1.039, 1.840) 0.026 1.309( 1.002, 1.711) 0.048
(Continued )
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DFS (Full model) DFS (Reduced model) 
HR(95%CI) P HR(95%CI) P
Gender (Women/Men) 0.787( 0.395, 1.568) 0.496   
Smoking (Smoker/Never) 1.319( 0.694, 2.508) 0.398   
Histology (Adeno/Sq) 3.730( 1.596, 8.722) 0.002 3.730( 1.599, 8.703) 0.002
     
pStat1score(High/Low) 1.124( 0.963, 1.312) 0.137 1.099( 0.957, 1.262) 0.18
pStage (II,III/I) 2.193( 1.297, 3.706) 0.003 2.377( 1.449, 3.901) 0.001
Adjuvant (Present/Absent) 1.405( 0.811, 2.436) 0.225   
Age (Unit=10) 1.308( 0.984, 1.737) 0.064 1.255( 0.961, 1.638) 0.096
Gender (Women/Men) 0.576( 0.289, 1.150) 0.118   
Smoking (Smoker/Never) 1.357( 0.714, 2.581) 0.351   
Histology (Adeno/Sq) 1.511( 0.753, 3.034) 0.246 1.108( 0.571, 2.148) 0.762
     
pStat3score(High/Low) 0.879( 0.567, 1.363) 0.565 0.779( 0.511, 1.188) 0.246
pStage (II,III/I) 2.152( 1.259, 3.677) 0.005 2.244( 1.359, 3.706) 0.002
Adjuvant (Present/Absent) 1.358( 0.779, 2.369) 0.281   
Age (Unit=10) 1.362( 1.031, 1.800) 0.03 1.301( 0.996, 1.699) 0.053
Gender (Women/Men) 0.706( 0.352, 1.419) 0.329   
Smoking (Smoker/Never) 1.575( 0.831, 2.984) 0.164   
Histology (Adeno/Sq) 1.505( 0.749, 3.026) 0.251 1.211( 0.615, 2.385) 0.58
Table 4: Results of Cox regression analysis for OS
 
 
OS (Full model) OS (Reduced model) 
HR(95%CI) P HR(95%CI) P
SUVmax(Unit=q3-q1) 1.232( 0.718, 2.113) 0.449 1.227( 0.738, 2.039) 0.431
pStage (II,III/I) 2.861( 1.330, 6.155) 0.007 2.383( 1.200, 4.729) 0.013
Adjuvant (Present/Absent) 0.781( 0.355, 1.717) 0.539   
Age (Unit=10) 1.068( 0.735, 1.553) 0.73   
Gender (Women/Men) 0.386( 0.134, 1.114) 0.078 0.283( 0.118, 0.681) 0.005
Smoking (Smoker/Never) 1.785( 0.716, 4.449) 0.214   
Histology (Adeno/Sq) 1.592( 0.645, 3.930) 0.313 1.396( 0.578, 3.369) 0.459
     
SUVmean(Unit=q3-q1) 1.224( 0.732, 2.047) 0.44 1.232( 0.753, 2.016) 0.405
pStage (II,III/I) 2.885( 1.348, 6.172) 0.006 2.396( 1.214, 4.729) 0.012
Adjuvant (Present/Absent) 0.777( 0.354, 1.708) 0.53   
Age (Unit=10) 1.068( 0.734, 1.552) 0.732   
Gender (Women/Men) 0.381( 0.133, 1.092) 0.072 0.283( 0.118, 0.678) 0.005
Smoking (Smoker/Never) 1.765( 0.710, 4.389) 0.221   
Histology (Adeno/Sq) 1.586( 0.646, 3.895) 0.314 1.397( 0.581, 3.360) 0.455
(Continued )
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OS (Full model) OS (Reduced model) 
HR(95%CI) P HR(95%CI) P
     
MTV(Unit=q3-q1) 1.255( 1.111, 1.416) <0.001 1.244( 1.111, 1.393) <0.001
pStage (II,III/I) 2.661( 1.216, 5.826) 0.014 2.076( 1.034, 4.167) 0.04
Adjuvant (Present/Absent) 0.645( 0.286, 1.455) 0.29   
Age (Unit=10) 0.959( 0.662, 1.390) 0.826   
Gender (Women/Men) 0.394( 0.141, 1.103) 0.076 0.325( 0.136, 0.773) 0.011
Smoking (Smoker/Never) 1.555( 0.622, 3.889) 0.345   
Histology (Adeno/Sq) 1.366( 0.588, 3.172) 0.468 1.236( 0.538, 2.840) 0.618
     
TLG(Unit=q3-q1) 1.177( 1.083, 1.280) <0.001 1.172( 1.083, 1.268) <0.001
pStage (II,III/I) 2.657( 1.209, 5.838) 0.015 2.047( 1.019, 4.113) 0.044
Adjuvant (Present/Absent) 0.647( 0.288, 1.457) 0.294   
Age (Unit=10) 0.966( 0.668, 1.397) 0.854   
Gender (Women/Men) 0.401( 0.145, 1.111) 0.079 0.331( 0.139, 0.790) 0.013
Smoking (Smoker/Never) 1.594( 0.642, 3.960) 0.315   
Histology (Adeno/Sq) 1.416( 0.614, 3.266) 0.415 1.249( 0.549, 2.842) 0.596
     
Glut1score(High/Low) 3.246( 1.389, 7.585) 0.007 3.569( 1.534, 8.304) 0.003
pStage (II,III/I) 2.744( 1.293, 5.821) 0.009 2.429( 1.249, 4.727) 0.009
Adjuvant (Present/Absent) 0.824( 0.373, 1.821) 0.632   
Age (Unit=10) 1.132( 0.781, 1.639) 0.513   
Gender (Women/Men) 0.437( 0.152, 1.257) 0.125 0.374( 0.152, 0.921) 0.032
Smoking (Smoker/Never) 1.376( 0.544, 3.480) 0.5   
Histology (Adeno/Sq) 3.236( 1.201, 8.720) 0.02 3.146( 1.169, 8.472) 0.023
     
pStat1score(High/Low) 1.222( 0.980, 1.524) 0.075 1.260( 1.022, 1.553) 0.031
pStage (II,III/I) 3.110( 1.485, 6.514) 0.003 2.725( 1.396, 5.322) 0.003
Adjuvant (Present/Absent) 0.755( 0.343, 1.663) 0.485   
Age (Unit=10) 1.039( 0.722, 1.495) 0.838   
Gender (Women/Men) 0.266( 0.090, 0.785) 0.017 0.226( 0.093, 0.551) 0.001
Smoking (Smoker/Never) 1.473( 0.603, 3.597) 0.396   
Histology (Adeno/Sq) 1.475( 0.635, 3.428) 0.366 1.328( 0.579, 3.048) 0.503
     
pStat3score(High/Low) 0.769( 0.393, 1.507) 0.444 0.815( 0.421, 1.578) 0.544
pStage (II,III/I) 2.959( 1.391, 6.292) 0.005 2.460( 1.257, 4.814) 0.009
Adjuvant (Present/Absent) 0.758( 0.345, 1.665) 0.49   
Age (Unit=10) 1.106( 0.773, 1.582) 0.582   
Gender (Women/Men) 0.395( 0.133, 1.171) 0.094 0.282( 0.117, 0.680) 0.005
Smoking (Smoker/Never) 1.786( 0.703, 4.537) 0.223   
Histology (Adeno/Sq) 1.414( 0.616, 3.250) 0.414 1.239( 0.544, 2.823) 0.609
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Glut1 or Ki-67 expression for predicting the prognosis 
of resected NSCLC patients [22]. Kaira et al. stated that 
SUVmax and Glut1 were independent prognostic factors 
for DFS in adenocarcinoma patients [8]. We consider that 
TLG, MTV and Glut1 are significant prognostic factors 
for DFS and OS in resected NSCLC patients.
In the present patients, pStat3 was not shown to 
be an independent prognostic factor. Galleges Ruiz et al. 
suggested that (1) the EGFR-Stat3 pathway may be related 
to the tumor growth of early NSCLC (2) pStat3-positive 
expression in NSCLC may indicate the indolent type, and 
(3) high pStat3 expression was significantly associated 
with longer OS and PFS [20]. Our data are partially 
in agreement with those of Galleges Ruiz et al. [23]. 
However, Xu et al. noted that high pStat3 expression is a 
strong predictor of poor prognosis among NSCLC patients 
[24]. This issue remains to be clarified.
pStat1 has been reported to be associated with poor 
prognosis in malignant tumors, and with chemotherapy 
resistance in lung cancer [7, 25, 26]. In the present study, 
we observed a significant difference between pStat1 
expression and OS in the multivariate analysis, but not 
between pStat1 expression and DFS. We speculate that 
pStat1 expression may be a significant prognostic factor 
for the OS of NSCLC patients, although pStat1 does not 
contribute to the 18F-FDG uptake mechanism.
There are some study limitations to consider. First, 
the study was retrospective, and our patient distribution 
was heterogeneous because of the inclusion of stage I–
IIIA patients and those who had undergone postoperative 
adjuvant therapy. We performed the statistical analysis 
using adjusted clinicopathological prognostic variables. 
Second, the measurement of the MTV has not been 
standardized. There are several tumor delineation 
methods for the MTV, which includes a manual method, 
an automatic method and a semiautomatic method. 
Fixed-threshold methods such as the use of the fixed cut-
off SUVmax of 2.5 and a fixed percentage of SUVmax 
thresholds (typically 40%–80%) have been used [27]. 
We used the threshold of 40% of SUVmax, because this 
method was used in the literature [28]. The fixed cut-off 
SUVmax of 2.5 for measuring 18F-FDG uptake lesions 
Table 5: The characteristic of NSCLC patients
 Number
Gender  
Men 85
Women 55
pStage  
IA 67
IB 24
IIA 19
IIB 6
IIIA 17
IIIB 7
Histological type  
Adeno 114
Sq 26
Smoking Status  
Never Smoker 63
Smoker 77
Chemotherapy after surgery  
Paclitaxel 3
Docetaxel 3
UFT 33
CDDP based chemotherapy 12
CBDCA based chemotherapy 1
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for MTV has been used in past investigations [17, 19]. 
However, 18F-FDG uptake lesions of NSCLC less than 
SUVmax 2.5 exist in clinical setting, and the chance of 
malignant lung nodule less than SUVmax 2.5 has been 
reported to be 62% [29]. In this study, we used the 
threshold 40% of SUVmax, because forty-eight of all 
140 NSCLC lesions (34%) were less than SUVmax 2.5. 
In addition, Laffron et al. suggested that a low threshold 
should be suitable for predicting treatment effects 
and survival in lung cancer patients, because the TLG 
variability is greater at high thresholds [27]. Paidpally 
et al. recently reported that there is excellent inter-reader 
agreement for the measurement of the MTV and TLG with 
40% and 50% SUVmax threshold segmentation [30]. The 
issue of which tumor delineation methods and cut-off 
values are best for predicting the prognosis or evaluating 
the tumor response after chemotherapy or radiotherapy 
should be investigated using more cases.
In conclusion, Glut1 and pStat3 are associated with 
the 18F-FDG uptake mechanism of NSCLC, and 18F-FDG 
uptake may predict the pStat3 expression level. TLG, 
MTV, and Glut1 may be independent prognostic factors in 
resected NSCLC patients.
MATERIALS AND METHODS
Cell culture and reagents
Human lung cancer cell lines were maintained under 
a humidified atmosphere of 5% CO2 at 37°C in RPMI 
1640 medium (HCC827, EBC1, NCI-H1993, Calu1, 
A549, NCI-H1975, PC9) supplemented with 10% fetal 
bovine serum (FBS). EBC1, A549, NCI-H1975, and PC9 
were kindly provided by M. Ono (Kyushu University, 
Fukuoka, Japan). Calu1 was kindly provided by Kazuhiko 
Nakagawa (Kindai University, Osaka, Japan). HCC827 
and NCI-H1993 were purchased from ATCC (Manassas, 
VA, USA). Cell cultures were routinely confirmed to 
be free of mycoplasma contamination with the use of a 
Mycosensor QPCR Assay Kit (Agilent Technologies, Santa 
Clara, CA, USA). The small interfering RNAs (siRNAs) 
corresponding to Glut1 and a non-specific siRNA (control) 
were purchased from Nippon Gene (Tokyo). Cells were 
transfected with siRNA duplexes using Lipofectamine 
RNAiMAX and Opti-MEM (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer's recommendations.
Patients
During the period from December 2006 to May 
2012, 202 NSCLC patients underwent 18F-FDG PET 
followed by surgical resection. Our inclusion criteria 
for the patients were as follows: Patients who had 
undergone (1) complete curative surgical resection and 
complete mediastinal lymph node resection, with (2) 
histopathological findings confirming adenocarcinoma or 
squamous cell carcinoma. The patients who underwent a 
partial lobectomy (n=13) or neoadjuvant chemotherapy 
before surgery (n=9) or who were not followed up at 
our institution (n=9) were excluded. Patients with other 
histopathological types (n=11), those with a past history 
of malignant tumors (n=10), and those with non-useable 
18F-FDG PET data due to trouble of data (n=10) were 
excluded. Our final study population was 140 NSCLC 
patients with a median age of 73 (range 42–91) years. The 
characteristics of the patients are summarized in Table 5. 
The pathological TNM stages were established using the 
International System for Staging Lung Cancer adopted by 
the American Joint Committee on Cancer [31]. This study 
was conducted according to the Declaration of Helsinki, 
and was approved by our institutional review board. The 
need for written informed consent was waived for this 
retrospective study.
18F-FDG PET imaging acquisition
A dedicated full-ring PET scanner (Allegro, Philips 
Medical Systems, Cleveland, OH, USA) were used for data 
acquisition. Before the 18F-FDG injection, the patient fasted 
for 4 hr. The median blood glucose level was 105 mg/dL 
(range 73–180). The patient was administered a median 
282 MBq (range 170–370) of 18F-FDG via the antecubital 
vein. The patient rested quietly for approximately 60 min 
after the 18F-FDG injection. PET emission scans of the 
areas from the level of the auditory meatus to the mid-
thigh were acquired with a time of 2 min 30 sec per cradle 
position using a three-dimensional acquisition mode. 
Transmission scans were carried out for all patients to 
provide attenuation correction with a 137Cs point source. 
After both the transmission and emission images were 
obtained, the images were reconstructed using the standard 
normal reconstruction protocol based on a 3D-RAMURA 
(Philips Eindhoven, The Netherlands) for PET.
18F-FDG PET image analysis
18F-FDG-PET images were displayed on a PET 
view workstation (Philips Medical Systems) on which a 
VOI was drawn over the entire abnormal uptake of the 
primary tumor to include a large amount of radioactivity 
on axial images semiautomatically. A threshold of 40% of 
the maximum peak activity within the lesions was used to 
delineate the MTV [27, 28]. The border of the VOI was 
adjusted manually by overlap with the adjacent 18F-FDG-
avid structures, physiological uptake, or lesions. The 
SUVmax, SUVmean, MTV and TLG of each lesion were 
calculated and recorded on the workstation.
Immunohistochemical staining
Histopathological specimens were obtained from 
surgically resected samples. Immunohistochemistry 
staining was performed. Paraffin-embedded tissue samples 
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were cut at 4 μm and examined on a coated slide glass, and 
labeled with the following antibodies using the BenchMark 
XT (Ventana Automated Systems, Tucson, AZ, USA) and 
a Bond-III autostainer (Leica Microsystems, Newcastle, 
UK): Glut1 (1:100, Thermo Scientific, Rockford, IL, 
USA), pStat1 (1:400, Cell Signaling Technology, Beverly, 
MA, USA), and pStat3 (1:200, Cell Signaling Technology).
For Glut1, the BenchMark XT was used. Briefly, 
each slide was heat-treated using Ventana's CC1 retrieval 
solution for 30 min, and incubated with the Glut1 antibody 
for 30 min. This automated system used the streptavidin 
biotin complex method with 3,3' diaminobenzidine 
(DAB) as the chromogen (Ventana UltraVIEW DAB 
detection kit). Immunostaining for pStat1 and pStat3 were 
performed on the same fully automated Bond-III system 
using onboard heat-induced antigen retrieval with epitope 
retrieval solution 2 (ER2) for 30 min and a Refine polymer 
detection system (Leica Microsystems) with horseradish 
peroxidase (HRP)-polymer as the secondary antibody and 
DAB.
The immunohistochemical staining examination 
result for Glut1 was evaluated as positive according to 
cytoplasm/membrane reactivity, and pStat1 and pStat3 
were evaluated as positive according to the nucleus 
reactivity. We evaluated the intensity of immunostaining 
as follows: 0, no staining; 1+, weak staining of <10% 
cancer cells; 2+, moderate staining of 10%–50% cancer 
cells; 3+, strong staining of >50% cancer cells. All 
immunohistochemical staining examination results were 
evaluated by two experienced observers who were blind to 
the condition of the patients. We calculated the respective 
scores for Glut1, pStat1, and pStat3 using the intensity 
multiplied by the immunostained area.
Statistical analysis
DFS was defined as the period from the date of the 
patient's surgery until the date of disease recurrence or 
death. OS was defined as the period between the dates 
of the surgery and death due to any cause. We classified 
the patients into pairs of groups: those with low and high 
values using the optimal cut-off value derived from the 
25th and 75th percentiles of the interquartile range (IQR; 
q1–q3) of the PET parameters and molecular markers 
expression.
The relationships between all PET parameters 
and various clinicopathological variables or molecular 
markers were evaluated using the Wilcoxon rant test and 
Spearman's rank correlation test. Using the cut-off values, 
we estimated the survival functions of OS and those of 
DFS for the low and high groups by the Kaplan-Meier 
method, and we compared these functions by the log-
rank test.
We used a Cox proportional hazard model 
(continuous PET parameter and molecular marker model) 
to evaluate the effects of PET parameters and molecular 
markers while adjusting for potential confounding factors. 
Differences at p<0.05 were regarded as significant. All 
analyses were conducted using SAS ver. 9.2 software 
(SAS Institute, Cary, NC, USA) and R ver. 2.13.0.
Abbreviations
TNM: tumor-node-metastasis; SUVmax: maximum 
standardized uptake value; SUVmean: mean standardized 
uptake value; TLG: total lesion glycolysis; MTV: 
metabolic tumor volume; Glut1: Glucose transporter-1; 
Stat1: Signal transducer and activator of transcription-1; 
pStat1: phosphorylated Stat1; JAK: Janus-activated 
kinase; INF: interferon; EGFR: epidermal growth 
factor receptor; pStat3: phosphorylated Stat3; pStage: 
pathological stage; HR: hazard ratio; CI: confidence 
interval; HIF-1α: hypoxia-inducible growth factor-1α; 
VEGF: vascular endothelial growth factor; mTOR: 
mammalian target of rapamycin; PTEN: phosphatase and 
tensin homolog; 3D-RAMURA: 3D row-action maximum 
likelihood algorithm; VOI: volumetric region of interest; 
DFS: Disease-free survival; OS: Overall survival; UFT: 
tegaful-uracil; CDDP: cisplatin; CBDCA: carboplatin; 
Adeno: adenocarcinoma; Sq: squamous cell carcinoma; 
R: Spearman rank coefficient; q1-q3: the 25th and 75th 
percentiles of the interquartile range: MIP: Maximum 
intensity projection.
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